My site

STAMFORD, CT - Friday, 02. February 2024

.

(BUSINESS WIRE) -- Philip Morris International Inc (PMI) (NYSE: PM) is pleased to announce that it has reached a global settlement with British American Tobacco p.l.c. (BAT) that resolves all ongoing patent infringement litigation between the parties related to our heated tobacco and vapor products.

Patent protection is a critical component of the innovation driving PMI’s strategies and the company welcomes this settlement as the best path forward for its business plans.

The settlement includes non-monetary provisions between PMI and BAT that resolve all ongoing global patent infringement litigation, encompassing all related injunctions and exclusion orders, and prevents future claims against current heated tobacco and vapor products. The settlement also allows each party to innovate and introduce product iterations. PMI is committed to continued innovation in reduced-risk products to further advance To ... Read more »

– Galderma reaffirms its dedication to continued Sculptra innovation and scientific advancement, exploring Sculptra’s regenerative properties and potential use in non-facial treatment areas –

(BUSINESS WIRE) -- Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare professionals and unmatched patient satisfaction. Sculptra is the first and original biostimulator, with a unique PLLA-SCA™ formulation that activates the skin’s natural power to revitalize collagen production for a more youthful appearance.

Sculptra has a unique journey in the aesthetics industry, originating as a volume replenishment treatment in 1999 to improve the life of AIDS patients experiencing facial wasting.1 Sculptra’s applications have evolved over the years to become the multifaceted treatment that it is today. As Galderma’s research and understanding of Sculpt ... Read more »

NEW YORK - Friday, 02. February 2024
New Research Center Aims to Deliver Breakthrough Advancements in Dermatology and Discover Solutions for Healthy and Allergic Skin

(BUSINESS WIRE)--Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-thinking research in dermatology, exploring the biological underpinnings of how skin ages, skin allergies and inflammatory or eczematous skin conditions, including eczema (or atopic dermatitis) and contact dermatitis. Rooted in a shared mission to conduct dermatological research that improves patients’ lives, the partnership will focus on applicable scientific discovery and leading-edge innovation to modernize allergy science in order to identify innovative solutions for these skin conditions.

Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims ... Read more »

 (BUSINESS WIRE) -- Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.

“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a ... Read more »